Sintilimab Plus Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer and Biomarker Exploration

References

• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Ren Z , XuJ, BaiYet al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol.22(7), 977–990 (2021).
   PubMed Web of Science ®Google Scholar
• Ajani JA , D'AmicoTA, BentremDJet al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw.20(2), 167–192 (2022).
   PubMed Web of Science ®Google Scholar
• Le DT , DurhamJN, SmithKNet al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science357(6349), 409–413 (2017).
   PubMed Web of Science ®Google Scholar
• Marabelle A , LeDT, AsciertoPAet al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol.38(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• Oaknin A , GilbertL, TinkerAVet al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J. Immunother. Cancer10(1), e003777 (2022).
   PubMed Web of Science ®Google Scholar
• Janjigian YY , KawazoeA, YañezPet al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature600(7890), 727–730 (2021).
   PubMed Web of Science ®Google Scholar
• Janjigian YY , ShitaraK, MoehlerMet al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet398(10294), 27–40 (2021).
   PubMed Web of Science ®Google Scholar
• Hasegawa H , ShitaraK, TakiguchiSet al. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer25(3), 619–628 (2022).
   PubMed Web of Science ®Google Scholar
• Jiang H , YuX, LiNet al. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J. Immunother. Cancer10(3), e003635 (2022).
   PubMed Web of Science ®Google Scholar
• Ding P , GuoH, SunCet al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol.22(1), 121 (2022).
   PubMed Web of Science ®Google Scholar
• Cunningham D , AllumWH, StenningSPet al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med.355(1), 11–20 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Batran SE , HomannN, PauligkCet al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet393(10184), 1948–1957 (2019).
   PubMed Web of Science ®Google Scholar
• Salas-Benito D , Pérez-GraciaJL, Ponz-SarviséMet al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov.11(6), 1353–1367 (2021).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , DvorkinM, ChenYet al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet394(10212), 1929–1939 (2019).
   PubMed Web of Science ®Google Scholar
• Zhou C , ChenG, HuangYet al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir. Med.9(3), 305–314 (2021).
   PubMed Web of Science ®Google Scholar
• Schmid P , RugoHS, AdamsSet al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.21(1), 44–59 (2020).
   PubMed Web of Science ®Google Scholar
• Hoy SM . Sintilimab: first global approval. Drugs79(3), 341–346 (2019).
   PubMed Web of Science ®Google Scholar
• Zhou C , WuL, FanYet al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J. Thorac. Oncol.16(9), 1501–1511 (2021).
   PubMed Web of Science ®Google Scholar
• Jiang H , ZhengY, QianJet al. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer20(1), 760 (2020).
   PubMed Web of Science ®Google Scholar
• Wang J , HeY, ZhangBet al. The efficacy and safety of sintilimab combined with nab-paclitaxel as a second-line treatment for advanced or metastatic gastric cancer and gastroesophageal junction cancer. Front. Oncol.12, 924149 (2022).
   PubMed Web of Science ®Google Scholar
• Gandara DR , PaulSM, KowanetzMet al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med.24(9), 1441–1448 (2018).
   PubMed Web of Science ®Google Scholar
• Yang J , GongY, LamVKet al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis.11(5), 346 (2020).
   PubMed Web of Science ®Google Scholar
• Leal A , van GriekenNCT, PalsgroveDNet al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat. Commun.11(1), 525 (2020).
   PubMed Web of Science ®Google Scholar
• Zhao D , YueP, WangTet al. Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer. J. Hematol. Oncol.14(1), 164 (2021).
   PubMed Web of Science ®Google Scholar
• Huffman BM , AushevVN, BuddeGLet al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis. Oncol.6, e2200420 (2022).
   PubMed Web of Science ®Google Scholar
• Lu Y , YuanX, WangMet al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J. Hematol. Oncol.15(1), 47 (2022).
   PubMed Web of Science ®Google Scholar
• Routy B , LeChatelier E, DerosaLet al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science359(6371), 91–97 (2018).
   PubMed Web of Science ®Google Scholar
• Zeng TM , YangG, LouCet al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat. Commun.14(1), 1340 (2023).
   PubMed Web of Science ®Google Scholar
• Fang X , ZhuN, ZhongCet al. Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial. EClinicalMedicine62, 102123 (2023).
   PubMedGoogle Scholar
• Li MM , DattoM, DuncavageEJet al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn.19(1), 4–23 (2017).
   PubMed Web of Science ®Google Scholar
• Xia Y , TangW, QianXet al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J. Immunother.Cancer10(4), e004656 (2022).
   PubMedGoogle Scholar
• Wang Y , YangL, BaoHet al. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study. PLoS Med.18(8), e1003741 (2021).
   PubMed Web of Science ®Google Scholar
• Ott PA , BangYJ, Piha-PaulSAet al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol.37(4), 318–327 (2019).
   PubMed Web of Science ®Google Scholar
• Zeng D , WuJ, LuoHet al. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J. Immunother. Cancer9(8), e002467 (2021).
   PubMed Web of Science ®Google Scholar
• Li W , DengY, ChuQ, ZhangP. Gut microbiome and cancer immunotherapy. Cancer Lett.447, 41–47 (2019).
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V , SpencerCN, NeziLet al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science359(6371), 97–103 (2018).
   PubMed Web of Science ®Google Scholar
• Tong Y , ZhuY, ZhaoYet al. Evaluation and comparison of predictive value of tumor regression grades according to Mandard and Becker in locally advanced gastric adenocarcinoma. Cancer Res. Treat.53(1), 112–122 (2021).
   PubMed Web of Science ®Google Scholar
• Jin Y , DongH, XiaLet al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J. Thorac. Oncol.14(8), 1378–1389 (2019).
   PubMed Web of Science ®Google Scholar
• Ychou M , BoigeV, PignonJPet al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol.29(13), 1715–1721 (2011).
   PubMed Web of Science ®Google Scholar
• Wan JCM , MassieC, Garcia-CorbachoJet al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer17(4), 223–238 (2017).
   PubMed Web of Science ®Google Scholar
• Kim ST , CristescuR, BassAJet al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med.24(9), 1449–1458 (2018).
   PubMed Web of Science ®Google Scholar
• Magbanua MJM , SwigartLB, WuHTet al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann. Oncol.32(2), 229–239 (2021).
   PubMed Web of Science ®Google Scholar
• Zeng D , LiM, ZhouRet al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol. Res.7(5), 737–750 (2019).
   PubMed Web of Science ®Google Scholar
• Zitvogel L , MaY, RaoultD, KroemerG, GajewskiTF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science359(6382), 1366–1370 (2018).
   PubMed Web of Science ®Google Scholar
• Matson V , FesslerJ, BaoRet al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science359(6371), 104–108 (2018).
   PubMed Web of Science ®Google Scholar